MEG3 hypermethylation was discovered to be present in 47.6% of AML cases, which may be related to a much worse overall survival rate in these patients, according to an analysis of the aberrant promoter methylation of MEG3 in 42 AML patients [135,136,137]. This evidence concerns the gene MEG3 and acute myeloid leukemia.